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Akt is well known to enhance malignancy and is recognized as a key target for antineoplastic therapies. However, intriguing 
findings reported by Yoeli-Lerner et al. in the November 23, 2005 issue of Molecular Cell, suggest a novel, antimetastasis func-
tion of Akt: activation of Akt1 inhibited invasion in some cancer cells. One possible mechanism for this surprising phenotype 
was that Akt activated the E3 ubiquitin ligase HDM2, causing ubiquitination and degradation of NFAT, an invasion-promoting 
factor. These findings clearly justify further investigations and, if validated in vivo, call for reevaluation of some Akt-targeting 
therapeutic strategies currently under development.Akt modulates a variety of cellular proc-
esses, including proliferation, growth, and 
survival, by phosphorylating target pro-
teins involved in these processes (recently 
reviewed in Bellacosa et al., 2004; Brazil 
et al., 2004; Osaki et al., 2004; Woodgett, 
2005). Many signaling pathways activate 
Akt through phosphatidylinositol-3-kinase 
(PI3K). PI3K converts phosphatidylinosi-
tol-4,5-bis-phosphate (PIP2) to phos-
phatidylinositol-3,4,5-triphosphate (PIP3). 
PIP3 recruits Akt to the membrane where 
Akt is activated. PTEN dephosphorylates 
PIP3 and antagonizes PI3K function. 
Additionally, several molecules, such as 
CTMP, TRB3, and PHLPP, bind to and 
directly regulate Akt (Brazil et al., 2004; 
Gao et al., 2005).
Well-characterized substrates of Akt 
include antiapoptotic proteins, such as 
FOXO, BAD, and IKK-β; cell cycle regula-
tors, such as p27kip1, p21cip1, MDM2, and 
Myt1; and GSK-3, which is involved in a cancer cell : december 2005 variety of processes (Brazil et al., 2004). 
Akt has also been shown to stimulate 
angiogenesis via regulation of eNOS 
and increase cell metabolism through 
the mTOR/p70S6K pathway (Luo et al., 
2003). Additionally, Akt stimulates MMP 
secretion, activates the small GTPase 
Rac, and promotes epithelial-to- mesen-
chymal transition (EMT), three attributes 
that can lead to increased metastatic 
potential (Bellacosa et al., 2004; Luo et 
al., 2003; Zhou et al., 2004). In light of 
Akt’s involvement in all these pathways, 
it is not surprising that Akt protein levels, 
enzymatic activities, and even gene copy 
numbers are increased in many different 
types of tumors. Akt upregulation has 
been seen in carcinomas of the prostate, 
breast, ovary, pancreas, colon, stomach, 
and thyroid (Luo et al., 2003; Osaki et 
al., 2004). The importance of increased 
Akt activity in tumorigenesis is further 
underscored by the identification of gain-of-function mutations in PI3K and loss of 
expression of the PTEN tumor suppressor 
gene in many tumors, which positively and 
negatively regulate Akt activation, respec-
tively (Luo et al., 2003; Osaki et al., 2004; 
Saal et al., 2005).
Given these well-established mecha-
nisms by which Akt activation promotes 
transformation, a publication by the Toker 
laboratory in the November 23, 2005 issue 
of Molecular Cell suggests a surprising 
twist on Akt’s role in the tumorigenic proc-
ess (Yoeli-Lerner et al., 2005). Compelling 
in vitro evidence indicates that Akt blocked 
motility and invasion, important metasta-
sis-related properties, in three different 
breast cancer cell lines. This was studied 
by artificially activating Akt1 and also by 
activating Akt with IGF-1 as a physiologi-
cal stimulus. Conversely, lowering Akt1 
levels with siRNA restored, and in some 
cases enhanced, the invasive properties 
of the cells. The kinase activity of Akt was 437
	 p r e v i e w srequired. The authors further investigat-
ed the mechanism of this Akt-mediated 
effect with a candidate gene approach. 
Using activated constructs and siRNA, 
they demonstrate the importance of two 
molecules, NFAT and HDM2, in invasion 
suppression by Akt. The Toker laboratory 
had previously discovered that the tran-
scription factor NFAT (nuclear factor of 
activated T cells) is downstream of α6β4 
integrin and promotes carcinoma invasion 
(Jauliac et al., 2002). In the current study, 
they demonstrate that Akt downregulates 
the transcriptional activity of NFAT by 
drastically reducing NFAT protein levels. 
Akt activation led to NFAT ubiquitination 
by HDM2 and targeted NFAT for degrada-
tion by the proteasome. HDM2, the human 
homolog of MDM2 (murine double minute 
2), is an E3 ubiquitin ligase and is regu-
lated by Akt (Ashcroft et al., 2002; Zhou 
et al., 2001). When HDM2 levels were 
lowered using siRNA, the same inva-
sion-promoting effect occurred as when 
Akt levels were reduced. Furthermore, 
the phenotype of cells with constitutively 
active Akt was partially reversed when 
HDM2 levels were reduced. Thus, HDM2 
is downstream of Akt in mediating inhibi-
tion of invasive behavior (Yoeli-Lerner et 
al., 2005).
These unexpected results may be 
important clinically if they hold when tested 
in other systems, particularly in vivo. While 
in vitro assays provide standard indicators 
of motility and invasiveness, strong state-
ments cannot be made about metastatic 
behavior without studying the process in 
a whole animal. Nevertheless, the current 
findings are in agreement with published 
work (Hutchinson et al., 2004) from the 
Muller lab using transgenic mouse mod-
els. In this analysis, bitransgenic mice with 
activated ErbB2 and activated Akt1, both 
driven by the mouse mammary tumor virus 
(MMTV) promoter, were generated. The 
bitransgenic mice developed mammary 
tumors with significantly shorter latency 
than mice with only activated ErbB2, and 
the bitransgenic tumors were more pro-
liferative than their ErbB2-induced coun-
terparts. Consistent with the findings in 
the current report, the bitransgenic mice 
with both activated Akt1 and ErbB2 had 
dramatically less lung metastasis from the 
mammary tumors than mice with activated 
ErbB2 alone (7% and 68%, respectively). 
However, the bitransgenic tumors were 
also more differentiated than the ErbB2-
induced tumors. The inverse relationship 
between differentiation and metastasis is 
well established; therefore, it is unclear 438 whether the decrease in metastasis in 
the bitransgenic mice was a direct effect 
of Akt signaling or a consequence of the 
differentiation state of the tumors.
Akt-mediated inhibition of metastatic 
properties is clearly cell type depend-
ent. Akt1 enhances the motility and 
invasion of other cell lines, including 
HT1080 fibrosarcoma cells. The in vivo 
study (Hutchinson et al., 2004) from the 
Muller laboratory does not rule out the 
possibility of a limited, cell type-specific 
effect because transgene expression 
is restricted to specific cells within the 
mammary gland. More interesting is the 
authors’ suggestion that different Akt iso-
forms (Akt1 versus Akt2) may modulate 
metastasis in opposing manners. Some 
isoform-specific roles have previously 
been demonstrated for the three Akt pro-
teins (Akt1, Akt2, and Akt3; also named 
protein kinase B α, β, and γ); however, 
there is no clear evidence that the pro-
teins have different substrate specifici-
ties. The different activities of the three 
Akts may arise from differences in their 
relative abundance in a given cell type, 
differential regulation once activated, or 
the capacity to be activated by different 
stimuli (Bellacosa et al., 2004; Brazil et 
al., 2004; Osaki et al., 2004). In the cur-
rent study, activated Akt1 was ectopically 
expressed, and the siRNA downregu-
lated endogenous Akt1 without affecting 
Akt2 levels (Yoeli-Lerner et al., 2005). 
In studies previously published by the 
Slamon laboratory, Akt2 increased inva-
sive behavior in culture and metastasis 
in vivo of a number of breast and ovarian 
cancer cell lines (Arboleda et al., 2003). 
Notably, the MDA-MB-231 cell line was 
tested in both studies and provides a 
direct comparison between the functions 
of Akt1 and Akt2 in determining meta-
static potential. Thus, an understanding 
of how the relative levels of Akt1 and Akt2 
influence motility, invasion, and metas-
tasis is a necessary avenue for future 
investigation. Collectively, these findings 
suggest that clinically applicable, iso-
form-specific Akt inhibitors need to be 
developed.
The current paper nicely shows the 
involvement of NFAT and HDM2 in Akt1 
inhibition of invasive behavior in breast 
cancer cell lines. However, it is unlikely 
that this is the whole story. Akt typically 
phosphorylates multiple molecules to 
regulate a single biological process. In 
light of this general theme of Akt action, 
further investigation of the mechanisms 
used by Akt proteins to modulate the met-astatic properties of transformed cells is 
necessary. Additionally, HDM2 ubiquiti-
nates other proteins, including p53, which 
inhibits malignancy (Ashcroft et al., 2002; 
Zhou et al., 2001). Therefore, the effects 
of Akt modulation of HDM2 may be very 
complicated. Nonbiased approaches may 
be the most informative way to elucidate 
the mechanisms and functions of Akt and 
HDM2 in these cells. Furthermore, it will 
be interesting to know if different stimuli 
upstream of Akt have distinct effects on 
Akt-mediated invasive properties.
If validated, the current findings could 
have important clinical implications. 
Inhibiting the Akt and PI3K pathway might 
be a double-edged sword that blocks 
tumorigenesis but promotes invasion. 
Therefore, it is imperative that the molecu-
lar mechanism be thoroughly understood 
in order to develop a molecular profile 
predictive of patient response to PI3K/Akt 
pathway inhibitors, thereby allowing pre-
cisely tailored cancer therapies.
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The rapid rise in melanoma incidence 
and the high lethality associated with 
advanced disease (reviewed in Thompson 
et al., 2005) has motivated efforts to 
define the genetic and environmental 
factors driving melanoma genesis and 
progression. It is generally accepted that 
melanoma risk is modulated by skin pig-
mentation patterns, such as those linked 
to MC1R polymorphisms (Palmer et al., 
2000), and early exposure to ultravio-
let (UV) light (reviewed in Thompson et 
al., 2005). Stereotypical genetic lesions 
in melanoma include disruption of the 
CDKN2A familial melanoma locus that 
encodes for INK4A and ARF; activation of 
MAPK pathway components, commonly 
at the levels of BRAF and NRAS; and acti-
vation of the PI3K-AKT pathway through 
loss of PTEN (reviewed in Chudnovsky 
et al., 2005; Gray-Schopfer et al., 2005). 
Beyond these well-known and validated 
genetic events, genome-wide high-reso-
lution technologies have been used 
to scan the highly complex melanoma 
genome, revealing the existence of addi-
tional genetic elements governing disease 
genesis and progression (Garraway et al., 
2005; Curtin et al., 2005; O.K. and L.C., 
unpublished data). These data show that 
the life history of melanoma is shaped by 
extensive chromosomal rearrangements, 
particularly recurrent chromosomal gains/
amplifications and losses/deletions. That 
these copy number alterations carry 
pathogenetic significance has been sub-
stantiated in a recent integrated genom-
ics approach that has identified MITF as 
a lineage survival oncogene amplified in 
melanoma (Garraway et al., 2005). With 
increasing resolution of array CGH plat-
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Hung, M.C. (2001). Nat. Cell Biol. 3, 973–982. forms for mapping chromosomal altera-
tions and advances in expression and 
sequencing technologies, it is anticipated 
that the discovery of novel melanoma rel-
evant genes will accelerate dramatically 
in the near future.
High-resolution charting of recurrent 
copy number aberrations by array CGH 
will also provide the basis for molecular 
classification that, when combined with 
clinical information, will define genotype-
phenotype correlation and biomarkers that 
can enhance existing staging systems for 
patient stratification. For example, correlat-
ing melanomas arising in different anatomi-
cal sites with different UV exposure patterns 
to distinct genomic signatures should lead 
to an understanding of the genetic modula-
tors and targets of UV’s mutagenic actions 
in this cancer. In the November 17 issue 
of The New England Journal of Medicine, 
Curtin et al. (2005) took an important first 
step in defining such gene-environment 
interactions in melanoma.
In this study, Curtin and colleagues 
conducted a genome-wide analysis of 
DNA copy number and mutational analy-
sis of BRAF and NRAS in 126 melanomas 
from individuals with varying UV exposure 
histories (Curtin et al., 2005). Distinctive 
patterns of genomic alterations as well as 
differences in frequencies of BRAF and 
NRAS mutations were observed among 
the four groups of melanomas examined. 
Genomic instability was most prominent 
in melanomas arising on skin protected 
from direct UV light. Specifically, acral 
melanomas of the palms and soles and 
mucosal melanomas exhibited high num-
bers of whole-genome gains and losses, 
intrachromosomal copy number changes, 
 heterogeneity of mela
rous recurrent chromosomal rearrangeme
nesis and response to therapy. High-reso
ecific mutational analyses, appear poise
mes, and set the stage for the design of ra
.Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., 
Gunduz, M., and Hung, M.C. (2004). Nat. Cell 
Biol. 6, 931–940.
DOI: 10.1016/j.ccr.2005.11.006439
and focal amplifications (Figure 1). On the 
other hand, amplifications and deletions 
were infrequent in melanomas arising on 
skin with chronic sun-induced damage (as 
defined by evidence of solar elastosis on 
histology) and those from skin with inter-
mittent UV exposure but without chronic 
damage (Figure 1). There were differences 
not only in the levels of genomic instability 
for the four melanoma subgroups, but also 
in their patterns of chromosomal gains 
and losses (Figure 1). Genomic clas-
sification was able to classify acral and 
mucosal melanomas with 89% accuracy. It 
was also possible to distinguish between 
melanomas from skin exhibiting signs of 
chronic sun-induced damage and those 
from skin without signs of damage with 
84% accuracy. That genomic signatures 
capable of classifying melanoma from dif-
ferent anatomic sites can be defined is a 
definitive proof that melanoma is a geneti-
cally heterogeneous disease.
In addition to their genomic patterns, 
the mutational spectrum was different 
between melanomas from sun-exposed 
and sun-protected skin (Figure 1). In par-
ticular, this study extended the group’s 
earlier findings that melanomas from 
chronically sun-exposed and non-sun-
exposed skin differed significantly in the 
mutation frequency of BRAF (Maldonado 
et al., 2003). In all melanoma groups, 
BRAF and NRAS mutations were found 
to be mutually exclusive. The presence of 
activating BRAF mutations inversely cor-
related with copy number gains of CCND1, 
and both events were associated with 
higher levels of CCND1 protein expression. 
Amplification of CDK4, encoding a CCND1 
binding partner, was commonly seen in 
noma
nts, and embedded within this complex-
lution genome-wide DNA copy number 
d to define keystone molecular events, 
tional therapies that may finally have an 
